Tower Research Capital (TRC)’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-8,937
| Closed | -$804 | – | 6417 |
|
|
2023
Q3 | $804 | Buy |
8,937
+1,080
| +14% | +$100 | ﹤0.01% | 5473 |
|
|
2023
Q2 | $723 | Sell |
7,857
-54
| -0.7% | -$9 | ﹤0.01% | 5563 |
|
|
2023
Q1 | $2K | Buy |
7,911
+11
| +0.1% | +$3 | ﹤0.01% | 5472 |
|
|
2022
Q4 | $2K | Sell |
7,900
-524
| -6% | -$131 | ﹤0.01% | 5524 |
|
|
2022
Q3 | $2K | Buy |
8,424
+5,995
| +247% | +$2.8K | ﹤0.01% | 5718 |
|
|
2022
Q2 | $2K | Sell |
2,429
-1,613
| -40% | -$1.37K | ﹤0.01% | 5711 |
|
|
2022
Q1 | $3K | Sell |
4,042
-1,566
| -28% | -$1.44K | ﹤0.01% | 5497 |
|
|
2021
Q4 | $6K | Sell |
5,608
-786
| -12% | -$1.11K | ﹤0.01% | 5118 |
|
|
2021
Q3 | $11K | Buy |
+6,394
| New | +$10.8K | ﹤0.01% | 4297 |
|
|
2021
Q2 | – | Sell |
-783
| Closed | -$2K | – | 6343 |
|
|
2021
Q1 | $2K | Buy |
+783
| New | +$1.83K | ﹤0.01% | 5133 |
|
|
2020
Q4 | – | Sell |
-1,317
| Closed | -$4K | – | 5657 |
|
|
2020
Q3 | $4K | Sell |
1,317
-2,241
| -63% | -$8.04K | ﹤0.01% | 4472 |
|
|
2020
Q2 | $14K | Buy |
+3,558
| New | +$6.8K | ﹤0.01% | 3887 |
|
|
2018
Q2 | – | Sell |
-744
| Closed | -$5K | – | 4352 |
|
|
2018
Q1 | $5K | Buy |
744
+493
| +196% | +$3.69K | ﹤0.01% | 2755 |
|
|
2017
Q4 | $2K | Sell |
251
-36
| -13% | -$305 | ﹤0.01% | 3290 |
|
|
2017
Q3 | $2K | Sell |
287
-2,167
| -88% | -$18.4K | ﹤0.01% | 3621 |
|
|
2017
Q2 | $25K | Buy |
+2,454
| New | +$24.3K | ﹤0.01% | 1117 |
|
|
2016
Q3 | – | Sell |
-1,953
| Closed | -$21K | – | 4943 |
|
|
2016
Q2 | $21K | Buy |
+1,953
| New | +$38.4K | ﹤0.01% | 2210 |
|
|
2016
Q1 | – | Sell |
-874
| Closed | -$23K | – | 5361 |
|
|
2015
Q4 | $23K | Buy |
874
+408
| +88% | +$14.2K | ﹤0.01% | 1173 |
|
|
2015
Q3 | $22K | Buy |
466
+304
| +188% | +$11.5K | ﹤0.01% | 1666 |
|
|
2015
Q2 | $5K | Buy |
162
+38
| +31% | +$1.1K | ﹤0.01% | 3298 |
|
|
2015
Q1 | $4K | Sell |
124
-150
| -55% | -$5.08K | ﹤0.01% | 3464 |
|
|
2014
Q4 | $10K | Sell |
274
-3,299
| -92% | -$90.7K | ﹤0.01% | 2190 |
|
|
2014
Q3 | $94K | Buy |
3,573
+2,649
| +287% | +$70.1K | 0.01% | 1033 |
|
|
2014
Q2 | $27K | Buy |
+924
| New | +$29.9K | ﹤0.01% | 1677 |
|
|
2014
Q1 | – | Sell |
-113
| Closed | -$5K | – | 5197 |
|
|
2013
Q4 | $5K | Buy |
113
+107
| +1,783% | +$4.19K | ﹤0.01% | 3571 |
|
|
2013
Q3 | $0 | Buy |
+6
| New | +$350 | ﹤0.01% | 5008 |
|
Other funds holding NAVB
Tower Research Capital (TRC)'s NAVB Position: Q4 2023 in Review
Tower Research Capital (TRC) sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 8,937 shares — an estimated $804 sold.
Tower Research Capital (TRC) first reported a position in NAVB in Q3 2013 and held it in 26 quarters. The position peaked at $94K in Q3 2014. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.
- Tower Research Capital (TRC) reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 8,937 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $804.
- Tower Research Capital (TRC) first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 26 quarters.
- Tower Research Capital (TRC)'s Navidea Biopharmaceuticals Inc. position peaked at $94K in Q3 2014.
- 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.